© 2003 by Oxford University Press
© 2003 Oxford University Press
BRIEF COMMUNICATION |
Selenium Supplementation and Secondary Prevention of Nonmelanoma Skin Cancer in a Randomized Trial
For the Nutritional Prevention of Cancer Study Group
Affiliations of authors: A. J. Duffield-Lillico, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY; E. H. Slate, Department of Biometry and Epidemiology, Medical University of South Carolina, Charleston; M. E. Reid, J. R. Marshall, Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY; B. W. Turnbull, School of Operations Research and Industrial Engineering, Cornell University, Ithaca, NY; P. A. Wilkins, M. S. Stratton, Arizona Cancer Center, Tucson, AZ; G. F. Combs, Jr., Grand Forks Human Nutrition Research Center, Grand Forks, ND; H. K. Park, Surgical Pathology, Eastern Dermatology and Pathology, Greenville, NC; E. G. Gross, Crystal Coast Dermatology Services, Morehead City, Medical Park Center, NC; G. F. Graham, Department of Dermatology, Wake Forest University Baptist Medical Center, Winston-Salem, NC.
Correspondence to: James R. Marshall, PhD, Roswell Park Cancer Institute, Carlton House Bldg., Rm. 304, Elm and Carlton Sts., Buffalo, NY 14263 (e-mail: james.marshall{at}roswellpark.org).
ABSTRACT
The Nutritional Prevention of Cancer Trial was a double-blind, randomized, placebo-controlled clinical trial designed to test whether selenium as selenized yeast (200 µg daily) could prevent nonmelanoma skin cancer among 1312 patients from the Eastern United States who had previously had this disease. Results from September 15, 1983, through December 31, 1993, showed no association between treatment and the incidence of basal and squamous cell carcinomas of the skin. This report summarizes the entire blinded treatment period, which ended on January 31, 1996. The association between treatment and time to first nonmelanoma skin cancer diagnosis and between treatment and time to multiple skin tumors overall and within subgroups, defined by baseline characteristics, was evaluated. Although results through the entire blinded period continued to show that selenium supplementation was not statistically significantly associated with the risk of basal cell carcinoma (hazard ratio [HR] = 1.09, 95% confidence interval [CI] = 0.94 to 1.26), selenium supplementation was associated with statistically significantly elevated risk of squamous cell carcinoma (HR = 1.25, 95% CI = 1.03 to 1.51) and of total nonmelanoma skin cancer (HR = 1.17, 95% CI = 1.02 to 1.34). Results from the Nutritional Prevention of Cancer Trial conducted among individuals at high risk of nonmelanoma skin cancer continue to demonstrate that selenium supplementation is ineffective at preventing basal cell carcinoma and that it increases the risk of squamous cell carcinoma and total nonmelanoma skin cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: Selenium Supplementation and Secondary Prevention of Nonmelanoma Skin Cancer in a Randomized Trial
- James Huff
J Natl Cancer Inst 2004 96: 333-334.[Extract] [Full Text] [PDF]
- RESPONSE: Re: Selenium Supplementation and Secondary Prevention of Nonmelanoma Skin Cancer in a Randomized Trial
- James Marshall, Mary Reid, and Anna Duffield-Lillico
J Natl Cancer Inst 2004 96: 334.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  C. H. Brown, S. M. Baidas, J. J. Hajdenberg, O. R. Kayaleh, G. K. Pennock, N. C. Shah, and J. E. Tseng Lifestyle Interventions in the Prevention and Treatment of Cancer American Journal of Lifestyle Medicine, September 1, 2009; 3(5): 337 - 348. [Abstract] [PDF]
|
|
|
|
 |
|
 S.-K. Myung, Y. Kim, W. Ju, H. J. Choi, and W. K. Bae Effects of antioxidant supplements on cancer prevention: meta-analysis of randomized controlled trials Ann. Onc., July 21, 2009; (2009) mdp286v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. van der Pols, M. M. Heinen, M. C. Hughes, T. I. Ibiebele, G. C. Marks, and A. C. Green Serum Antioxidants and Skin Cancer Risk: An 8-Year Community-Based Follow-up Study Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1167 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bockhorn, B. Balar, D. He, E. Seitomer, P. R. Copeland, and T. G. Kinzy Genome-wide screen of Saccharomyces cerevisiae null allele strains identifies genes involved in selenomethionine resistance PNAS, November 18, 2008; 105(46): 17682 - 17687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Boosalis The Role of Selenium in Chronic Disease Nutr Clin Pract, April 1, 2008; 23(2): 152 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hercberg, K. Ezzedine, C. Guinot, P. Preziosi, P. Galan, S. Bertrais, C. Estaquio, S. Briancon, A. Favier, J. Latreille, et al. Antioxidant Supplementation Increases the Risk of Skin Cancers in Women but Not in Men J. Nutr., September 1, 2007; 137(9): 2098 - 2105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Vogt, R. G. Ziegler, B. H. Patterson, and B. I. Graubard Racial Differences in Serum Selenium Concentration: Analysis of US Population Data from the Third National Health and Nutrition Examination Survey Am. J. Epidemiol., August 1, 2007; 166(3): 280 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chen, M. Hall, J. H. Graziano, V. Slavkovich, A. van Geen, F. Parvez, and H. Ahsan A Prospective Study of Blood Selenium Levels and the Risk of Arsenic-Related Premalignant Skin Lesions Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 207 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Griffiths, R. A. Matulka, and R. Power Acute and Subchronic Toxicity Studies on Sel-Plex(R), a Standardized, Registered High-selenium Yeast International Journal of Toxicology, November 1, 2006; 25(6): 465 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Fakih, L. Pendyala, P. F. Smith, P. J. Creaven, M. E. Reid, V. Badmaev, R. G. Azrak, J. D. Prey, D. Lawrence, and Y. M. Rustum A Phase I and Pharmacokinetic Study of Fixed-Dose Selenomethionine and Irinotecan in Solid Tumors Clin. Cancer Res., February 15, 2006; 12(4): 1237 - 1244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. McNaughton, G. C. Marks, and A. C. Green Role of Dietary Factors in the Development of Basal Cell Cancer and Squamous Cell Cancer of the Skin Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1596 - 1607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F. Combs Jr Current Evidence and Research Needs to Support a Health Claim for Selenium and Cancer Prevention J. Nutr., February 1, 2005; 135(2): 343 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lippman, P. J. Goodman, E. A. Klein, H. L. Parnes, I. M. Thompson, A. R. Kristal, R. M. Santella, J. L. Probstfield, C. M. Moinpour, D. Albanes, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT) J Natl Cancer Inst, January 19, 2005; 97(2): 94 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T. Jacobs, R. Jiang, D. S. Alberts, E. R. Greenberg, E. W. Gunter, M. R. Karagas, E. Lanza, L. Ratnasinghe, M. E. Reid, A. Schatzkin, et al. Selenium and Colorectal Adenoma: Results of a Pooled Analysis J Natl Cancer Inst, November 17, 2004; 96(22): 1669 - 1675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Taylor, H. L. Parnes, and S. M. Lippman Science Peels the Onion of Selenium Effects on Prostate Carcinogenesis J Natl Cancer Inst, May 5, 2004; 96(9): 645 - 647. [Full Text] [PDF]
|
|
|
|
|
|
J. Huff Re: Selenium Supplementation and Secondary Prevention of Nonmelanoma Skin Cancer in a Randomized Trial J Natl Cancer Inst, February 18, 2004; 96(4): 333 - 334. [Full Text] [PDF]
|
|